ArticlePharmaceutical biology2017
Assessment of luteolin isolated from Eclipta alba leaves in animal models of epilepsy.
Article in Pharmaceutical biology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 59 citations in OpenAlex.
- The modern scientific interpretation of ancient wisdom: a review of the phytochemistry and pharmacology of Erzhi Pill and its constituent botanical drugs.Frontiers in pharmacology · 2026Review
- Apigenin Regulating PI3K/AKT Pathway to Improve Depressive Behavior in Epileptic Rats.Combinatorial chemistry & high throughput screening · 2026Article
- Article
- Therapeutic Expedition of Luteolin against Brain-related Disorders: An Updated Review.Combinatorial chemistry & high throughput screening · 2025Review
- Flavonoids and Alzheimer's disease: reviewing the evidence for neuroprotective potential.Molecular and cellular biochemistry · 2025Review
- Recent Advances in Bioactive Flavonoids-based Nanotherapeutics as Promising Neuroprotectants in Epilepsy.Current aging science · 2025Review
- Green Synthesis and Characterization of Silver Nanoparticles from Eclipta alba and Its Activity Against Triple-Negative Breast Cancer Cell Line (MDA-MB-231).Molecular biotechnology · 2024Article
- Role of Plant Phytochemicals: Resveratrol, Curcumin, Luteolin and Quercetin in Demyelination, Neurodegeneration, and Epilepsy.Antioxidants (Basel, Switzerland) · 2024Review
- Natural flavonoids as potential therapeutics in the management of Alzheimer's disease: a review.3 Biotech · 2024Review
- Unlocking Therapeutic Potential: Comprehensive Extraction, Profiling, and Pharmacological Evaluation of Bioactive Compounds fromPlants (Basel, Switzerland) · 2023Review
- Treating Epilepsy with Natural Products: Nonsense or Possibility?Pharmaceuticals (Basel, Switzerland) · 2023Review
- Proanthocyanidins alleviate pentylenetetrazole-induced epileptic seizures in mice via the antioxidant activity.Neurochemical research · 2022Article
- Neuroprotective Natural Products' Regulatory Effects on Depression via Gut-Brain Axis Targeting Tryptophan.Nutrients · 2022Review
- Potential Therapeutic Benefits of Honey in Neurological Disorders: The Role of Polyphenols.Molecules (Basel, Switzerland) · 2022Review
- Review
- Investigation on the Anticonvulsant Potential of Luteolin and Micronized Luteolin in Adult Zebrafish (Danio rerio).Neurochemical research · 2021Article
- Inhibition of microglia overactivation restores neuronal survival in a mouse model of CDKL5 deficiency disorder.Journal of neuroinflammation · 2021Article
- Natural Medicines for the Treatment of Epilepsy: Bioactive Components, Pharmacology and Mechanism.Frontiers in pharmacology · 2021Review
- Paving Luteolin Therapeutic Potentialities and Agro-Food-Pharma Applications: Emphasis onOxidative medicine and cellular longevity · 2021Review
- In vitro anticancer activity of Eclipta alba whole plant extract on colon cancer cell HCT-116.BMC complementary medicine and therapies · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextEclipta alba (Linn) Hassk. (Asteraceae) has been reported to be a nerve tonic and has been used to treat epilepsy in folk medicine.
objectiveThe present study isolates and characterizes luteolin from E. alba and evaluates its antiepileptic potential in chemically induced acute and chronic models in mice. MATERIALS AND
methodsThe methanol extract (16.85% w/w) of E. alba leaves was subjected to fractionation for isolation of luteolin. In acute pentylenetetrazole (PTZ) model, luteolin (5, 10, 20 mg/kg, i.p.) was administered 30 min prior to PTZ injection (100 mg/kg) in Swiss albino mice. Kindling was induced by chronic administration of PTZ (35 mg/kg) on every alternate day (48 days). Luteolin was investigated on the course of kindling development and oxidative stress markers [reduced glutathione (GSH) and malondialdehyde (MDA)] in kindled mice.
resultsSingle-dose pretreatment with luteolin (10 and 20 mg/kg, i.p.) was found to be effective in an acute PTZ model (100% protection from mortality) and it did not exhibit any effect on motor coordination at the same doses. PTZ-induced kindling was significantly (p < 0.001) prevented by luteolin (5, 10, 20 mg/kg, i.p.) in a dose-dependent manner. Luteolin restored levels of reduced GSH (p < 0.001) and decreased the level of MDA (p < 0.001), a marker of lipid peroxidation. DISCUSSION AND
conclusionThe results of the present study demonstrated that luteolin had an anticonvulsant effect in an acute PTZ model. Luteolin exhibited and inhibitory effect on the course of kindling and associated oxidative stress and hence could be a potential molecule in the treatment of epilepsy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.